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ARTICLE OPEN
p53-mediated redox control promotes liver regeneration and
maintains liver function in response to CCl4
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Thomas G. Bird2,4, Karen Blyth2,3 and Karen H. Vousden 1✉
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The p53 transcription factor coordinates wide-ranging responses to stress that contribute to its function as a tumour suppressor.
The responses to p53 induction are complex and range from mediating the elimination of stressed or damaged cells to promoting
survival and repair. These activities of p53 can modulate tumour development but may also play a role in pathological responses to
stress such as tissue damage and repair. Using a p53 reporter mouse, we have previously detected strong induction of p53 activity
in the liver of mice treated with the hepatotoxin carbon tetrachloride (CCl4). Here, we show that p53 functions to support repair and
recovery from CCl4-mediated liver damage, control reactive oxygen species (ROS) and limit the development of hepatocellular
carcinoma (HCC), in part through the activation of a detoxification cytochrome P450, CYP2A5 (CYP2A6 in humans). Our work
demonstrates an important role for p53-mediated redox control in facilitating the hepatic regenerative response after damage and
identifies CYP2A5/CYP2A6 as a mediator of this pathway with potential prognostic utility in human HCC.
Cell Death & Differentiation; https://doi.org/10.1038/s41418-021-00871-3
INTRODUCTION
The TP53 (p53) transcription factor coordinates diverse aspects of
the cellular stress response and is capable of engaging both pro-
survival and pro-death pathways [1]. Although p53 was initially
identified through its association with cancer, it also has broader
roles in organismal health. p53 is required for efficient implanta-
tion of embryos into the uterus [2], promotes stamina during
exercise [3, 4], limits fibrosis after chronic liver injury [5], and
protects against Listeria monocytogenes infection [6]. Conversely,
unrestrained activation of p53 in embryos is rapidly lethal [7–9],
p53 promotes B-cell apoptosis in type 2 diabetes mellitus [10], and
in ischaemia, inhibition of p53 is protective [11–13]. These
disparate outcomes suggest a nuanced balance between diver-
gent aspects of p53 activity.
The liver provides an excellent setting in which to examine the
intersection of p53 signalling in cancer and normal biology.
Disruption of TP53 is observed in 30–40% of human hepatocellular
carcinomas (HCCs) [14], suggesting tumour-suppressive functions
for p53 in the liver. Indeed, the loss of hepatic p53 alone is
sufficient to promote liver cancer in mice, albeit at long latency
[15]. Even so, wild-type p53 is retained in more than half of human
HCCs, with a previously identified TP53 gene expression signature
characterising this group [14]. These observations suggest that
aspects of p53 function may also support—or at least not directly
antagonise—hepatic tumourigenesis.
Although the liver is largely quiescent in adults, it can
undergo rapid regeneration after damage or resection [16]. As
in HCC, the p53 pathway has been reported to support and
antagonise liver regeneration. It has been shown that p53
limits liver damage after acetaminophen overdose and
protects mitotic fidelity after partial hepatectomy, indicating
protective roles for p53 in the hepatic injury response [17–19].
Similarly, p53-deficient mice exhibit enhanced sensitivity to
high-dose irradiation during CCl4-induced regeneration [20]. In
addition, the loss of CDKN1A/p21, a p53 target, has been
reported to impair liver regeneration in certain liver damage
models [21, 22]. However, robust activation of p21 has also
been shown to promote senescence and to limit the
regenerative response, and p21 loss can allow for survival
after severe liver damage—suggesting that this arm of the p53
response may also impede liver regeneration [21, 23]. More
directly, unrestrained activation of p53 is lethal in hepatocytes,
p53-mediated apoptosis contributes to disease progression in
a model of non-alcoholic steatohepatitis, and p53 activity
promotes fibrosis in a model of chronic regeneration in rats
[24–27]. Thus, the role of p53 in the hepatic response to toxic
damage is not clear and may be dependent on the nature and
severity of the initiating damage.
Here, we utilise CCl4-mediated liver regeneration as a model
system to investigate the function of p53 in liver biology. Our work
demonstrates a role for p53-mediated redox control in facilitating
the hepatic regenerative response after damage. We identified
CYP2A5/CYP2A6 as a mediator of this pathway with potential
prognostic utility in human HCC.
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RESULTS
Liver-specific loss of p53 exacerbates liver damage and
increases ROS during CCl4-mediated liver regeneration
Using a p53 reporter mouse, we have previously detected strong
induction of the p53 pathway, albeit without clear accumulation
of p53 itself, in hepatocytes of mice treated with the hepatotoxin
carbon tetrachloride (CCl4). To explore the potential roles for p53
function during this process, we created mice harbouring liver-
specific deletion of Trp53 (p53) (Albumin-Cre; p53FL/FL mice),
confirmed that recombination of the p53 floxed allele was highly
efficient in the liver (Fig. S1A/B) and proceeded to characterise the
acute response to CCl4-mediated liver toxicity using this model
(Figs. 1A/B and S1 C–H). Importantly, mice of either p53 genotype
developed normally and were histologically indistinguishable
prior to treatment (Fig. S1 C/D). Within the first 24 h following
treatment with CCl4, Albumin-Cre; p53
WT/WT mice (p53 WT) mice
exhibited evident liver damage, including vacuolisation, neutro-
phil infiltration, and destruction of Glutamine Synthetase (GS)-
positive peri-central vein hepatocytes (Figs. 1A/B and S1C–H).
Damage progressed outward from the central vein over the first
48–72 hours after treatment before resolving within the remainder
of the 168-h time-course (Figs. 1A/B and S1 C/D). In Albumin-Cre;
p53FL/FL mice, although GS-positive hepatocyte destruction and
damage-associated neutrophil infiltration were similar to p53 WT
mice (Fig. S1E–H), liver damage progressed outward from the peri-
central vein region more rapidly, coalescing into larger regions of
injury at 24 h after CCl4 treatment (Figs. 1A/B and S1 C/D). Even so,
the liver damage in Albumin-Cre; p53FL/FL mice also resolved within
168 h.
To confirm our histological assessment of liver damage, we
examined the presence of alanine and aspartate transaminase
(ALT/AST) activity in blood plasma, two markers of liver damage. In
agreement with the liver histology, we noted extended elevation
of plasma ALT and AST activity in Albumin-Cre; p53FL/FL mice
(Fig. 1C/D), suggesting elevated liver damage in these mice. Even
so, as observed in liver histology, plasma ALT and AST levels
ultimately normalised by 168 h after treatment in mice of both
genotypes, suggesting potentially significant but transient effects
of p53 during CCl4-mediated liver regeneration. These findings are
consistent with previous reports of p53 acting to limit liver
damage after acetaminophen overdose [18, 19], where p53
exerted short-lived protective effects.
One of the features of damage-mediated liver regeneration is
the dramatic but transient microvesicular steatosis that occurs
prior to initiation of the proliferative phase of the regenerative
response [28–30]. The resulting accumulation of lipids can be
visualised as red puncta in oil-red O-stained liver sections. In
contrast to our liver damage assessments, we observed a similar
peak accumulation of oil-red-O staining at 24 h after CCl4
treatment in the livers of Albumin-Cre; p53WT/WT and Albumin-
Cre; p53FL/FL mice (Fig. 1E/F). However, while lipid levels rapidly
normalised by 48 h after treatment in Albumin-Cre; p53WT/WT mice,
elevated oil-red-O staining persisted in Albumin-Cre; p53FL/FL mice
for an additional 2 days (Fig. 1E/F).
The initial reductive dehalogenation of CCl4 generates short-
lived but highly reactive intermediates that potently oxidise lipids
and cause DNA damage [31, 32]. Peroxidized lipids can impede
mitochondrial function, including fatty acid oxidation, and impair
lipid export—potentially contributing to lipid accumulation during
CCl4 detoxification [33–35]. Considering the established role for
p53 supporting the redox response [36], we investigated whether
the disrupted lipid clearance in Albumin-Cre; p53FL/FL mice was a
consequence of decreased ROS detoxification. Indeed, levels of
malondialdehyde (MDA), a marker of lipid peroxidation, were
elevated to a greater extent, and for an additional two days, in
Albumin-Cre; p53FL/FL mice compared with Albumin-Cre; p53WT/WT
mice (Fig. 1G/H).
To investigate the contribution of ROS stress to deficiencies in
liver regeneration in Albumin-Cre; p53FL/FL mice, we compared CCl4-
mediated regeneration between Albumin-Cre; p53FL/FL mice given
normal drinking water to those provided with N-Acetylcysteine
(NAC)-supplemented drinking water. NAC treatment is an estab-
lished antidote to liver toxicity that results from acetaminophen
overdose in humans and functions by maintaining liver glutathione
levels during the detoxification process [37]. As expected, NAC
treatment significantly attenuated lipid peroxidation in Albumin-
Cre; p53FL/FL mice (Fig. 1I/J). NAC treatment also promoted
significantly more rapid clearance of lipid droplets (Fig. 1K/L),
suggesting that redox management is an important feature of the
p53-mediated response to hepatic CCl4 toxicity.
Liver p53 engages Cyp2a5/CYP2A6 to support redox control
during CCl4-mediated liver regeneration
Given the differences in redox control between Albumin-Cre;
p53WT/WT and Albumin-Cre; p53FL/FL mice at 24 h after CCl4
treatment, we focused on the early response to toxicity. At 8 h
after CCl4 treatment, we observed similar oil-red-O staining to
baseline and comparable lipid peroxidation between livers taken
from Albumin-Cre; p53WT/WT and Albumin-Cre; p53FL/FL mice
(Fig. 2A/B), suggesting that bifurcation of the regenerative
response had not yet occurred. Bulk RNA-seq analysis at this time
point identified 13 significant differentially regulated genes
between Albumin-Cre; p53WT/WT and Albumin-Cre; p53FL/FL livers 8
h after CCl4 treatment (Fig. S2A). Clustering analysis stratified
these genes into three groups, one of which contained p53 itself
and four established p53 targets: Ccng1/Cyclin G1, Eda2r, Zmat3/
Wig-1, and Abcb1a/Mdr1 [38–41] (Fig. 2C). Our attention was
drawn to the remaining member of this cluster, Cyp2a5, encoding
a cytochrome P450 enzyme that is induced by NFE2L2 (NRF2) to
aid in the murine redox response during ethanol detoxification
[42, 43]. CYP2A6, the human orthologue of Cyp2a5 [44], has been
shown to be a transcriptional target of p53 [45], suggesting
potential p53-directed functions for Cyp2a5 in the mouse as well.
Consistent with our RNA-seq data, we confirmed that expres-
sion of Cyp2a5 was induced in Albumin-Cre; p53WT/WT mice within
the first 8–24 h after CCl4 treatment, with later induction observed
in Albumin-Cre; p53FL/FL mice alongside increased levels of the
NRF2 target gene Nqo1 (Fig. S2B/C). Through IHC staining, we
confirmed higher levels of CYP2A5 protein in livers of Albumin-Cre;
p53WT/WT compared to Albumin-Cre; p53FL/FL mice within 24 h after
CCl4 treatment as well (Fig. 2D/E). CYP2A5 levels remained
significantly elevated in Albumin-Cre; p53WT/WT livers at 48 and
72 h after treatment, with a delayed increase evident in Albumin-
Cre; p53FL/FL livers at 48–72 h after CCl4 treatment (Fig. 2D/E).
Interestingly, although we observed potent early induction of
the p53 target gene Cdkn1a/p21 in Albumin-Cre; p53WT/WT mice,
this was matched by similar induction in Albumin-Cre; p53FL/FL
mice, a finding that we confirmed by IHC staining for p21 at 8 h
after CCl4 treatment (Fig. S2D/E). These findings suggest that early
expression of p21 after CCl4 treatment is p53-independent
(Fig. S2D/E), in contrast to its p53-dependent induction later in
the regenerative process (Fig. S2D). These results also explain why
Cdkn1a was not differentially expressed in our RNA-seq analysis.
Expression of CYP2A5, in contrast, was elevated in Albumin-Cre;
p53WT/WT mice but significantly lower in Albumin-Cre; p53FL/FL livers
at this time point, consistent with our RNA-seq data (Fig. S2F).
Bbc3/Puma, a pro-apoptotic p53 target gene that has been shown
to play a role in modulating liver metabolism in human HCC [46],
was not differentially expressed between Albumin-Cre; p53WT/WT
and Albumin-Cre; p53FL/FL mice during CCl4-mediated regeneration
(Fig. S2G), reinforcing the idea that not all aspects of p53 activity
are engaged during liver regeneration.
In the Mdm2Ex5/6Δ mouse model, excision of Mdm2 exons 5 and
6 (Mdm2Ex5/6Δ), comprising the p53-binding domain of MDM2,
T.J. Humpton et al.
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leads to rapid stabilisation of p53, robust expression of p53 target
genes, and ultimately in p53-dependent lethality within 4–5 days
[24, 47]. RNA-seq analysis of mice sampled at two days after
treatment with liver-specific AAV8-TBG-Cre [48] to induce expres-
sion of Mdm2Ex5/6Δ, a time point before widespread liver attrition,
confirmed significant induction of Cyp2a5. Indeed, we identified
all of the genes in our CCl4 RNA-seq analysis, alongside classical
p53 targets such as p21 and Puma in this alternative model
(Fig. S2H). As in the CCl4 liver regeneration model, we validated
the induction of p21 and CYP2A5, as well as stabilisation of p53,
via IHC (Fig. S2I–K). Combined, these findings confirm that
activation of p53 engages CYP2A5 in the liver.
T.J. Humpton et al.
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To explore the role of CYP2A5/CYP2A6 in damaged hepatocytes
more fully in vitro, we turned to HepG2 and SK-Hep-1 cells, human
HCC cell lines that maintain wild type p53 [46] (Fig. 2F/G).
Treatment of these cells with Nutlin, a direct activator of p53 [49],
induced expression of CDKN1A/p21, as expected, as well as
CYP2A6. Treatment of both HepG2 and SK-Hep-1 cells with CCl4
also induced p21 and CYP2A6 expression (Fig. 2F/G). This response
was abrogated following siRNA-mediated depletion of TP53,
confirming the role of p53 in the upregulation of p21 and CYP2A6
expression in response to CCl4 in vitro (Fig. 2F/G).
Functionally, both HepG2 and SK-Hep-1 cells treated with CCl4
exhibited increased ROS levels, and this was exacerbated in
CYP2A6-depleted cells (Fig. 2H/I). Treatment of HepG2 and SK-
Hep-1 cells with cumene hydroperoxide (CH), a stable organic
oxidising agent [50], similarly engaged CYP2A6 and CDKN1A/p21
(Fig. S2 L/M), and CYP2A6-depletion also increased cellular ROS
levels after CH treatment (Fig. 2J/K)—suggesting that downstream
ROS, rather than CCl4 directly, promotes activation of CYP2A6 to
aid in ROS detoxification. Interestingly, although induction of
CYP2A6 was p53-dependent in response to CCl4 treatment,
CYP2A6 increased independently of p53 after CH treatment
(Fig. S2L/M). Since hydroperoxides have been shown to activate
NRF2 in HepG2 cells [51], this finding is consistent with an
established role for NRF2-induced Cyp2a5 supporting the redox
response during ethanol detoxification in mice [42, 43]. Based on
these findings, we concluded that the p53-dependent activation
of CYP2A5 in response to CCl4 treatment in vivo contributed to the
enhanced detoxification of lipid ROS in support of rapid
regeneration in Albumin-Cre; p53WT/WT mice.
Hepatocyte p53 protects liver function and limits
tumourigenesis following CCl4-mediated chronic regeneration
A close relationship has been described between chronic
regeneration and cancer—with tumourigenesis sometimes con-
ceptualised as ‘a wound that does not heal’ [52]. While we
detected clear defects in redox control and liver function during
one round of CCl4 treatment and regeneration in Albumin-Cre;
p53FL/FL mice compared to Albumin-Cre; p53WT/WT mice, these
differences were transient and resolved within one week (Fig. 1).
In contrast to acute damage, repeated regeneration resulting from
regular CCl4 treatment causes lasting fibrotic liver damage, leading
to cirrhosis and HCC [53, 54]. This progression is exacerbated by
systemic DNA damage, chronic inflammation, and ROS stress
[55, 56]. With these findings in mind, we investigated the effects of
lack of liver p53 on fibrosis and HCC development in the well-
established CCl4 chronic liver regeneration model [5] (Fig. S3A).
One week after the conclusion of the 10-week chronic
regeneration regime, we observed striking generalised hepatocyte
hypertrophy [57] throughout the livers of Albumin-Cre; p53FL/FL
mice that was absent in similarly treated Albumin-Cre; p53WT/WT
mice (Fig. 3A/B). In hepatic stellate cells (HSCs), p53 has been
shown to limit fibrosis after chronic regeneration in the liver [5].
However, we found that hepatocyte-specific p53 loss did not lead
to differences in activated HSC content, as evaluated by IHC
staining for alpha-smooth muscle actin (aSMA), or to increased
fibrosis as assessed by picrosirius red staining (PSR) (Fig. 3B–D). In
fact, we observed a modest decrease in fibrosis in Albumin-Cre;
p53FL/FL mice (Fig. 3B/D), consistent with a previous report
showing that hepatocyte p53 can enhance fibrosis during CCl4-
mediated chronic regeneration in rats [27]. Although murine
hepatocyte p53 does not appear to limit fibrosis after chronic
regeneration either, we nevertheless detected higher levels of
unresolved DNA damage, measured by IHC staining for phospho-
histone H2A.X (gH2AX), increased lipid peroxidation (measured by
MDA) and—as expected—decreased levels of CYP2A5 in livers
from Albumin-Cre; p53FL/FL mice (Fig. 3E/F). Functionally, we also
found that plasma levels of ALT and AST enzyme activity were
both elevated in Albumin-Cre; p53FL/FL mice after chronic
regeneration, consistent with compromised liver function in these
mice (Fig. 3G).
In wild-type mice, it can take up to 2 years for HCC to arise from
chronic CCl4 treatment [58]. Consistent with this, few Albumin-Cre;
p53WT/WT mice (3/14) reached clinical endpoint within 550 days
after initial CCl4 treatment in our experimental cohorts (Fig. 4A). In
contrast, Albumin-Cre; p53FL/FL mice exhibited accelerated and
highly penetrant development of liver tumours in this timeframe
Fig. 1 Loss of liver p53 exacerbates liver damage and increases ROS during CCl4-mediated liver regeneration. Representative H&E images
(A) and quantification (B) of damaged area (% per field) in livers from Albumin-Cre; p53WT/WT mice (WT) and Albumin-Cre; p53FL/FL (FL) mice at
indicated times (hours) following CCl4 treatment. Damaged areas outlined. Scale bars 100 μm. Higher magnification inset images highlight
centrilobular liver damage including vacuolisation (black arrows). These images are taken from different H&E slides than those depicted for
damaged area. Scale bars 10 μm. Images reproduced without annotation and at full size in Fig. S1 C/D. Quantifications from N= 2 untreated (0
h) mice/group, N= 6 mice/group at 24 h, N= 5 WT and N= 4 FL mice at 48 h, N= 7 mice/group at 72 h, N= 3 mice/group at 168 h. Data
presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak’s multiple comparisons test and multiplicity-adjusted p values.
****p < 0.0001. Plasma ALT (C) and AST (D) activity (mU/mL) in Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice treated as in (A).
N= 3 untreated (0 h) mice/group. N= 4 mice/group/time point thereafter. Each data point represents the mean from technical duplicates per
mouse. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak’s multiple comparisons test and multiplicity-
adjusted p-values. *p < 0.05, **p < 0.01, ****p < 0.0001. Staining (E) and quantification of stain area (F) of frozen sections for oil-red-O (ORO) in
Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice treated as in (A). Scale bars 20 μm. Quantification from N= 5 untreated (0 h), 24
h, and 48 h mice/group, N= 7 mice/group at 72 h, and N= 3 mice/group at 168 h. Data presented as mean ± SEM and analysed using two-way
ANOVA with Holm-Sidak’s multiple comparisons test and multiplicity-adjusted p values. *p < 0.05, ***p < 0.001. Data from p53FL/FL mice also
used in (L) (normal water) but different representative images are shown. IHC staining (G) and quantification (H) of malondialdehyde (MDA) in
Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice at indicated times (hours) after CCl4 treatment. Scale bars 20 μm. Quantification
from N= 6 untreated (0 h) mice/group, N= 7 WT and N= 6 FL mice at 24 h, N= 7 mice/group at 48 and 72 h, and N= 3 mice/group at 168 h.
Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak’s multiple comparisons test and multiplicity-adjusted p
values. **p < 0.01, ****p < 0.0001. Data from p53FL/FL mice also used in (J) (normal water) but different representative images are shown. IHC
staining (I) and quantification (J) of malondialdehyde (MDA) in Albumin-Cre; p53FL/FL (FL) mice given control (water) or 30mM N-Acetylcysteine-
supplemented drinking water (NAC) for one week prior to CCl4 treatment. Images from indicated times (hours) after CCl4 treatment. Scale bars
20 μm. Quantification from N= 6 water and N= 2 NAC untreated mice (0 h), N= 6 water and N= 4 NAC mice at 24 h, N= 7 water and N= 4
NAC mice at 48-72 h. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak’s multiple comparisons test and
multiplicity-adjusted p-values. **p < 0.01, ****p < 0.0001. Data from p53FL/FL (normal water) mice also used in (H) but different representative
images are shown. Staining (K) and quantification (L) of oil-red-O (ORO) in Albumin-Cre; p53FL/FL (FL) mice given control (water) or 30mM N-
Acetylcysteine-supplemented drinking water (NAC) for one week prior to CCl4 treatment. Images from indicated times (hours) after CCl4
treatment. Scale bars 20μm. Quantification from N= 5 untreated water (0 h) and N= 2 untreated NAC mice, N= 5 water and N= 4 NAC mice
at 24 and 48 h, N= 7 water and N= 4 NAC mice at 72 h. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak’s
multiple comparisons test and multiplicity-adjusted p-values. *p < 0.05. Data from p53FL/FL (normal water) mice also used in (F) but different
representative images are shown.
T.J. Humpton et al.
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Fig. 2 Liver p53 engages Cyp2a5/CYP2A6 to support redox control during CCl4-mediated liver regeneration. Staining (A) and
quantification (B) for malondialdehyde (MDA) and oil-red-O (ORO) in Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice at 8 h after
CCl4 treatment. Scale bars 10μm. Representative of N= 3 WT and N= 4 FL mice. Data presented as mean ± SEM and analysed using two-tailed
t-tests and the Sidak–Bonferroni method to account for multiplicity of tests. ns not significant. C Clustering analysis of significant differentially
expressed genes (adjusted p < 0.05) from RNA-seq analysis between Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice at 8 h after
CCl4 treatment. Samples from N= 3 WT and N= 4 FL mice included in analysis. Positive Z-score values correspond to genes enriched in livers
of mice of the genotype indicated in the sample name. Cyp2a5-associated cluster as indicated. For further information, see materials and
methods. IHC staining (D) and quantification (E) of CYP2A5 in Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice at indicated times
(hours) after CCl4 treatment. Scale bars 20 μm. Quantification from N= 4 untreated (0 h) mice/group, N= 5 mice/group at 24 h, N= 7 mice/
group at 48 and 72 h, and N= 3 mice/group at 168 h. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm–Sidak’s
multiple comparisons test and multiplicity-adjusted p values. ***p < 0.001, ****p < 0.0001. RT-qPCR analysis of expression of TP53, CDKN1A and
CYP2A6 relative to ACTIN in HepG2 (F) and SK-Hep-1 (G) cells treated with siRNA against TP53, CYP2A6 (2A6), or non-targeting control (NT) 96 h
prior to analysis and additionally treated with either DMSO control (UT), CCl4 (4 mM), or with Nutlin (10 μM) for 24 h prior to analysis. N= 3
independent samples/condition. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak’s multiple comparisons
test and multiplicity-adjusted p values. *p < 0.05, **p < 0.01, ****p < 0.0001. Measurement of cellular ROS levels relative to baseline using the
CellROX fluorescent probe in HepG2 (H) and SK-Hep-1 (I) cells treated with non-targeting control (NT) or CYP2A6 (2A6) siRNA for 96 hours and
additionally treated with either DMSO control (UT) or with CCl4 (4 mM) in DMSO for 24 h prior to analysis. N= 5 independent HepG2 and N=
3 SK-Hep-1 samples/condition. Data presented as median fluorescent intensity (MFI) ± SEM relative to untreated NT cells and analysed using
two-way ANOVA with Holm–Sidak’s multiple comparisons test and multiplicity-adjusted p values. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001. Measurement of cellular ROS levels relative to baseline using the CellROX fluorescent probe in HepG2 (J) or SK-Hep-1 cells (K) treated
with non-targeting control (NT) or CYP2A6 (2A6) siRNA for 96 h and additionally treated with either DMSO control (UT) or with cumene
hydroperoxide (10 μM) (CH) for 24 h prior to analysis. N= 3 independent samples/condition in HepG2 cells and N= 4/condition in SK-Hep-1
cells. Data presented as median fluorescent intensity (MFI) ± SEM relative to untreated NT cells and analysed using two-way ANOVA with
Holm–Sidak’s multiple comparisons test and multiplicity-adjusted p values. **p < 0.01, ***p < 0.001, ****p < 0.0001.
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(9/9 mice, median survival 380 days after first CCl4 treatment)
(Fig. 4A). Most mice of both genotypes (2/3 Albumin-Cre; p53WT/WT
mice and 5/9 Albumin-Cre; p53FL/FL mice) reaching clinical
endpoint exhibited large tumour lesions but also retained non-
tumour (normal-like) tissue (Fig. S3B). These regions were sampled
as ‘tumour’ and ‘non-tumour’ tissue for subsequent analyses. At
the experiment endpoint (550 days after initial treatment), most
CCl4-treated Albumin-Cre; p53
WT/WT mice (11/14), all untreated
Albumin-Cre; p53WT/WT mice (10/10), and most untreated Albumin-
Cre; p53FL/FL mice (13/14) remained alive.
Non-tumour liver tissue from Albumin-Cre; p53FL/FL mice
retained the molecular features observed at the conclusion of
the CCl4 treatment regime, including prominent hypertrophy in
remaining normal hepatocytes (Fig. 4B) and significantly reduced
CYP2A5 expression (Fig. 4B, E). Analysis of tumours from Albumin-
Cre; p53WT/WT mice (2 from mice at clinical endpoint and 2 small
focal tumours identified at experiment endpoint) revealed that
expression of CYP2A5 was elevated and MDA staining was low
compared to tumours arising in Albumin-Cre; p53FL/FL mice
(Fig. 4C–E and Fig. S3C). These results confirmed that the
disparate features of regeneration in Albumin-Cre; p53FL/FL mice
—namely elevated ROS, persistent liver damage, and decreased
CYP2A5 expression—continued during tumourigenesis.
The p53-mediated expression of BBC3/PUMA has been shown to
promote a pro-cancer metabolic switch in human HCC, correlating
with poor prognosis in patients [46]. However, we did not observe
differential expression of murine Bbc3 in endpoint HCC tumours
arising in Albumin-Cre; p53WT/WT mice after chronic CCl4 treatment
compared with those in Albumin-Cre; p53FL/FL mice (Fig. S3D).
Expression of Cdkn1a/p21, in contrast, was elevated in the tumours
of Albumin-Cre; p53WT/WT mice (Fig. S3D). These findings suggest
that in murine HCC arising from chronic CCl4 treatment the p53-
PUMA mediated metabolic switch [46] is not a defining feature of
p53 WT HCC.
CYP2A6 expression is prognostically favourable and clusters
with a subset of p53-induced genes that correlate with
increased survival in human HCC
Given the strength of the association between increased survival,
retention of p53, and expression of CYP2A5 in the murine CCl4
chronic regeneration model, we examined whether high expres-
sion of CYP2A6 correlated with increased survival in human HCC
patients. Utilising the HCC dataset available through the cancer-
genome atlas (TCGA-LIHC dataset [59]), we confirmed that high
expression of CYP2A6 was associated with significantly greater
median survival in HCC (Fig. 4F). In addition, by stratifying the
Fig. 3 Loss of liver p53 leads to hepatic hypertrophy, chronic ROS and DNA damage, and impaired liver function after CCl4-mediated
chronic regeneration. A Quantification of relative hepatocyte size in Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice at 7 days
after completion of 10-week CCl4 chronic regeneration regime. N= 9 mice/genotype. Data presented as mean ± SEM and analysed using an
unpaired two-tailed t-test with Welch’s correction. **p < 0.01. B H&E and IHC staining for alpha-smooth muscle actin (aSMA), and picrosirius red
(PSR) staining in Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice at 7 days after completion of 10-week CCl4 chronic
regeneration regime. Scale bars 10 μm. Images representative of N= 10 WT and N= 8 FL mice for H&E, N= 4 WT and N= 5 FL mice for aSMA,
and N= 7 mice/group for PSR. C Quantification of IHC staining for aSMA in Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice from
(B) at either 7 days after completion of 10-week CCl4 chronic regeneration regime (chronic) or in untreated age-matched mice (control). N= 5
control mice/genotype, N= 4 WT and N= 5 FL chronic mice. Data presented as mean ± SEM and analysed using two-way ANOVA with
Holm–Sidak’s multiple comparisons test and multiplicity-adjusted p values. **p < 0.01. D Quantification of staining for picrosirius red (PSR) in
Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice as in (C). N= 4 control mice/genotype and N= 7 chronic CCl4 mice/genotype.
Data presented as mean ± SEM and analysed using two-way ANOVA with Holm–Sidak’s multiple comparisons test and multiplicity-adjusted p
values. **p < 0.01, ***p < 0.001, ****p < 0.0001. Images (E) and quantification (F) of IHC staining MDA, CYP2A5, and gH2AX in Albumin-Cre;
p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice at 7 days after completion of 10-week CCl4 chronic regeneration regime as in (C). Scale bars
20 μm. N= 4 mice/group for MDA, N= 7 mice/group for CYP2A5, and N= 9 mice/group for gH2AX. Data presented as mean ± SEM and
analysed using two-tailed t-tests and the Sidak–Bonferroni method to account for multiplicity of tests. **p < 0.01, ****p < 0.0001. G Plasma ALT
and AST activity (mU/mL) in Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice at 7 days after completion of 10-week CCl4 chronic
regeneration regime. N= 7 mice/group. Each data point represents the mean from technical duplicates per mouse. Data presented as mean ±
SEM and analysed using two-tailed t-tests and the Sidak–Bonferroni method to account for multiplicity of tests. ***p < 0.001.
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TCGA dataset between patients with disrupted TP53 (mutation or
loss) and those with WT TP53, we further determined that high
expression of CYP2A6 and retention of WT TP53 coincided with
increased survival compared with all other combinations of
tumours harbouring low expression of CYP2A6 and/or loss of WT
TP53 (Fig. 4G).
Previous work utilising TCGA data has focused on the genomic
determinants of human HCC [14]. In these analyses, the authors’
identified a ‘p53-induced gene target expression signature’ as part of
an aim to improve the clustering of HCC based on molecular and
biological attributes [14]. Using the TCGA-LIHC dataset, we examined
the relationship between these 20 identified p53-induced genes and
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CYP2A6 expression and found that CYP2A6 expression clustered with
a subset of the p53-induced genes including GADD45B, ALDH4A1,
GADD45A, ESR1, PANK1, and ACAD11 (Fig. 4H). Interestingly, although
high expression of the full p53-induced gene target expression
signature correlated with significantly reduced median survival in the
TCGA-LIHC dataset (Fig. 4I), we found that high expression of the
CYP2A6-associated gene cluster instead correlated with improved
median survival (Fig. 4J). Taken together, these observations are
consistent with a role for p53 and CYP2A6 in limiting liver cancer.
DISCUSSION
Tissue regeneration recapitulates many features of tumourigen-
esis, including potent activation of proliferative signalling path-
ways, changes to cellular metabolism, and rapid cell growth [60].
With this overlap in mind, we have examined the function of the
canonical tumour suppressor protein p53 during regeneration.
Using the liver as a model system, we have interrogated non-
tumour roles for p53 activity during both the acute and chronic
responses to the liver toxin and carcinogen CCl4. We identified
p53-mediated redox control and induction of CYP2A5/CYP2A6 as
important features of the hepatic p53 response both in vivo and in
human liver cancer cell lines in vitro.
Our findings suggest that a p53 programme is active during the
priming phase of acute CCl4-mediated regeneration that includes
induction of Cyp2a5, a cytochrome P450 enzyme that can be
induced to control ROS in the liver [42, 43, 61]. In TP53 WT human
HCC cell lines in vitro, we show that CYP2A6, the human
orthologue to murine Cyp2a5, is similarly engaged in a p53-
dependent manner in response to CCl4 or Nutlin treatment, as
well as in response to treatment with a ROS-inducing agent,
cumene hydroperoxide. In treated cells, the loss of CYP2A6
exacerbates redox stress, confirming the role of CYP2A6 in
supporting ROS control. Consistent with this observation, we
show that p53 acts to limit the propagation of CCl4-mediated
damage by controlling resulting ROS. These ROS-control activities,
likely alongside additional functions of p53, promote rapid
regeneration and restoration of normal liver function that is
delayed in the absence of liver p53.
Our results are somewhat at odds with a previous report where
Cyp2a5 was not shown to play a significant role in the hepatic
response to CCl4 toxicity [62]. However, this study examined
CYP2A5 activity only at 24 h after administration of a significantly
smaller dose of CCl4 to initiate acute regeneration—leading to
markedly less liver damage than observed in our model. This
discrepancy raises the interesting possibility that p53 activation
may require a threshold of liver damage, ROS, or other stimuli to
be sufficiently engaged. Given that DNA damage occurs during
CCl4 toxicity, the severity of induced DNA damage may play a role,
and future work examining this prospect could clarify the
activating signals that direct p53 during liver regeneration.
During the repeated damage of CCl4-mediated chronic liver
regeneration, we found that the paradigms identified in acute
regeneration persist. The presence of hepatic p53 does not limit,
but rather leads to a slight increase in fibrosis in our model.
Nevertheless, as in acute regeneration, p53 continues to engage
CYP2A5, restrict lipid peroxidation, and maintain liver architecture
and function. These protective actions are blunted in livers that
lack p53, leading to pervasive hepatocyte hypertrophy, chronically
increased ROS, unresolved DNA damage, and ultimately to
mortality from liver cancer. Thus, in our system, increased fibrosis
is not required for increased tumourigenesis. Further work is
warranted to more carefully examine the relationship between
fibrosis, p53 signalling, and liver tumourigenesis.
Our findings generalise to human HCC, where high expression
of CYP2A6 correlates with increased median survival, as well as
increased survival in the subset of patients that retain WT TP53
and maintain high expression of CYP2A6. These results suggest
that increased CYP2A6 expression is an important component of
p53’s tumour-suppressive function. Even so, our results also
suggest that elevated CYP2A6 alone is not sufficient to substitute
for p53 activity in limiting liver tumorigenesis, consistent with the
diverse repertoire of p53 tumour-suppressive activities in the cell.
We have further distinguished a group of six genes previously
reported as part of a p53-induced gene signature in human HCC
[14] whose expression clusters with CYP2A6 and together account
for improved median survival—in contrast with the poor
prognosis associated with high expression of the entire gene set.
Fig. 4 Liver p53 controls ROS, maintains expression of CYP2A5, and limits tumourigenesis following CCl4-mediated chronic
regeneration. A Survival curve comparing Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice that were either untreated (UT)
or administered the 10-week CCl4 chronic regeneration regime and aged until either reaching clinical endpoint or 550 days after initiation of
treatment. Data presented as time (days) since initial CCl4 injection. N= 10 WT and N= 14 FL untreated mice, N= 14 WT and N= 9 FL chronic
CCl4-treated mice. Of these, 0/10 WT and 1/14 FL UTmice and 3/14 WT and 9/9 FL CCl4-treated mice reached clinical endpoint within 550 days.
All WT tumour mice (3/3) and the majority of FL endpoint tumour mice (5/9) exhibited focal tumour lesions along with substantial non-
tumour (normal-like) tissue. These regions were sampled as ‘tumour’ and ‘non-tumour’ tissue for subsequent analyses. Within these cohorts, N
= 4 WT and N= 4 FL untreated mice were examined at ~365 days and confirmed to be tumour free. Data analysed using Log-rank
(Mantel–Cox) test. ****p < 0.0001. H&E and IHC staining for MDA and CYP2A5 in non-tumour liver tissue (B) and tumour tissue (C) from
Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (p53FL/FL) mice at clinical endpoint or 550 days post-treatment initiation after prior
completion of 10-week CCl4 chronic regeneration regime. Scale bars 20 μm. Images representative of N= 5 mice/group except N= 4 WT
tumours (2 from mice at clinical endpoint and 2 small focal tumours identified at experiment endpoint). Additional tumour images included in
Supplemental Fig. 3B to illustrate staining from the diversity of tumours observed in the model. Quantification of IHC staining for MDA (D) and
CYP2A5 (E) in Albumin-Cre; p53WT/WT (WT) and Albumin-Cre; p53FL/FL (FL) mice from (B/C). Data presented as mean ± SEM and analysed using
two-way ANOVA with Holm–Sidak’s multiple comparisons test and multiplicity-adjusted p values. *p < 0.05, **p < 0.01. F Survival curve
comparing HCC patients in the TCGA-LIHC dataset with high vs. low expression of CYP2A6 (2A6) on the basis of median survival. N= 91
CYP2A6 high and N= 73 CYP2A6 low patients. Data analysed using the Log-rank (Mantel–Cox) test. ***p < 0.001. G Survival curve comparing
HCC patients in the TCGA-LIHC dataset on the basis of TP53 status (loss or mutation of p53 (mutant) vs. WT TP53 (not mutant)) and further
breakdown of high vs. low expression of CYP2A6 (2A6) on the basis of median survival. N= 69 2A6 high, not mutant, N= 22 2A6 high, TP53
mutant, N= 50 2A6 low, not mutant, and N= 23 2A6 low, TP53 mutant. Data analysed using the Log-rank (Mantel-Cox) test. **p < 0.01, ***p <
0.001. H Clustering analysis of expression of CYP2A6 related to the previously identified 20 gene ‘p53-Induced Gene Target Expression
Signature’ [14] using the TCGA-LIHC dataset. CYP2A6-associated cluster as indicated. For further information, see materials and methods.
I Survival curve comparing HCC patients in the TCGA-LIHC dataset on the basis of high vs. low expression of the ‘p53-Induced Gene Target
Expression Signature’ [14]. N= 85/79 patients in the high and low groups. This analysis is independent of patient p53 status and includes all
data in the TCGA-LIHC dataset. Data analysed using the Log-rank (Mantel–Cox) test. ***p < 0.001. J Survival curve comparing HCC patients in
the TCGA-LIHC on the basis of high vs. low expression of the subset of genes within the ‘p53-Induced Gene Target Expression signature’ that
clustered with CYP2A6 expression in (H). N= 91/73 patients in the high and low groups. Data analysed using the Log-rank (Mantel–Cox) test.
*p < 0.05.
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Focusing on this point, we were surprised that high expression of
the whole p53 gene signature significantly reduced median patient
survival. However, it has been shown that p53 can help to protect
cancer cells from nutrient starvation [63, 64], reduce cell death from
ferroptosis [65, 66], and enhance redox control to limit ROS [67, 68]. In
addition, common tumour-derived p53 mutants have been found to
retain aspects of WT p53 function that promote adaptation to
metabolic stress [69, 70]. With these findings in mind, and considering
that ‘pro-tumourigenic’ p53 is an established paradigm in skin
carcinogenesis [71–73], it is conceivable that aspects of p53 function
can also enhance tumourigenesis in the liver. Future work investigat-
ing this possibility is warranted.
In humans, expression of CYP2A6 and of various CYP2A6
polymorphisms have been linked to higher rates pancreatic and
colorectal cancer but to mostly reduced rates of lung and
oesophageal cancer [74–78]. These findings suggest tissue, and
potentially carcinogen-specific, functions for CYP2A6 in limiting or
promoting tumourigenesis. In the liver, our findings suggest that
expression of CYP2A6 is beneficial. One method to infer CYP2A6
activity non-invasively is through the analysis of CYP2A6-derived
urinary metabolites of caffeine [74, 75]. Increased consumption of
coffee reduces the risk of developing HCC [79]. As such, it would
be interesting to examine whether caffeine consumption pro-
motes CYP2A6 expression. If so, this pathway could account for
some of the protective features of coffee consumption against
HCC. Future work examining this relationship, as well as whether
CYP2A6 activity in HCC patients has prognostic or stratification
value, is warranted.
Taken together, our results underscore the importance of p53
for maintaining liver function following damage. Interestingly, in
contrast to previous models showing that the tumour suppressor
function of p53 is a reflection of its ability to drive the elimination
of damaged cells [80], our work shows that the repair and survival
activities of p53 can also suppress the development of HCC.
MATERIALS AND METHODS
Mice
Procedures involving mice were performed under Home Office licence
numbers 70/8645, PP6345023, and 70/8891. Experiments were conducted
in accordance with the Animals (Scientific Procedures) Act 1986 and the EU
Directive 2010 and sanctioned by Local Ethical Review Process (University
of Glasgow). Mice were housed on a 12-h light/12-h dark cycle and
provided with normal chow diet and water ad libitum. Mice were
genotyped by Transnetyx (Cordova, TN).
p53FL/FL (Trp53tm1Brn), Albumin-Cre (Speer6-ps1Tg(Alb-cre)21Mgn), and
Mdm2Ex5/6Δ (Mdm2tm2.1Glo) mice were described previously [47, 81, 82].
For acute CCl4-mediated liver regeneration, mice were treated as previously
described [53, 83]. In brief, young male Albumin-Cre; p53WT/WT and Albumin-Cre;
p53FL/FL mice (approx. 70 days old) were given CCl4 (1mL/kg from stock
solution of 20% CCl4 v/v in corn oil) (Sigma cat# 289116 and C8267) via a single
intraperitoneal (IP) injection administered in the morning. Mice receiving NAC-
supplemented drinking water were provided with 30mM NAC (Sigma cat#
A7250) in water ad libitum for 72 h prior to treatment with CCl4 and
throughout the recovery period after treatment.
For chronic CCl4-mediated liver regeneration, young male Albumin-Cre;
p53WT/WT and Albumin-Cre; p53FL/FL mice (approx. 70 days old) were treated
weekly with IP injections of CCl4 (1mL/kg from stock solution of 20% CCl4 v/v
in corn oil) for 10 consecutive weeks. Separate cohorts of mice were either
sampled 7 days after the final injection or monitored until reaching clinical
endpoint (or 550 days after the first injection) and sampled at this time.
Cohorts were composed of fully backcrossed C57BL/6J (N10) Albumin-Cre;
p53WT/WT and Albumin-Cre; p53FL/FL male mice. Some mice from both
genotypes also contained the Rosa26LSL-tdRFP (Gt(ROSA)26Sortm1Hjf) reporter
allele [84], which did not affect the response to CCl4 treatment. The
experimental unit in all of our analyses was the individual mouse. No statistical
test was performed to predetermine sample size. Initial pilot studies suggested
a strong effect of liver p53 status on the response to CCl4 treatment 24–72 h
after administration, and subsequent experiments were performed using
sample sizes based on standard protocols in the field. No animals were
excluded from analysis. Within each experiment, mice were age and littermate
matched as much as possible, and all treated at the same time. Downstream
analyses were performed on a random order of samples blinded to the
genotype and treatment regime until the summation of results.
For Mdm2Ex5/6Δ RNA-seq experiments, mice homozygous for the
Mdm2tm2.1Glo allele were bred on a mixed background. 8–12 week old
male mice were injected with either AAV8.TBG.PI.Cre.rBG (Addgene,
107787-AAV8) or AAV8.TBG.PI.Null.bGH (Addgene, 105536-AAV8) at a dose
of 2 × 1011 genetic copies/mouse, as described previously [23]. Male mice
of the same age and genotype, but without AAV injection, served as
baseline controls (Untreated/uninduced controls). All mice were eutha-
nized at 48 h post-AAV injection via CO2 inhalation.
Recombination PCR
For recombination PCR, liver DNA from Albumin-Cre; p53WT/WT mice (WT)
and liver and kidney DNA from Albumin-Cre; p53FL/FL (p53FL/FL) adult mice
were isolated as previously described [85]. DNA was amplified using KOD
Hot Start Master Mix (Merck Millipore cat# 71842) according to standard
protocols. PCR primers were previously described [86].
Liver function assays (ALT/AST)
ALT and AST activity were determined in EDTA-treated plasma using the
Alanine Transaminase Activity Assay Kit (ab105134) and the Aspartate
Aminotransferase Activity Assay Kit (ab138878) from Abcam. Both assays
were performed following the manufacturer’s recommendations. Samples
were run together, analysed in duplicate wells per mouse sample, and the
mean value of these technical replicates was used for subsequent analysis.
Immunohistochemistry (IHC) and special staining
Staining for oil-red-O was performed on 10 μm frozen sections that were
first fixed for 5 min in 10% neutral buffered formalin (Solmedia), rinsed in
tap water, and then briefly rinsed in 60% isopropanol (Fisher Chemicals).
Slides were stained in freshly prepared and filtered oil-red-O staining
solution (0.5% w/v oil-red-o (Merck Life Science, UK) in isopropanol (Fisher
Chemicals)) for 15 min with agitation. Slides were subsequently blotted,
rinsed with 60% isopropanol and then water, before application of Mayers
Haematoxylin (Sigma Aldrich) to stain the nuclei. Stained slides were first
sealed using Aqueous mountant (Dako) and left overnight before being
coverslipped using DPX mountant (CellPath, UK).
Staining for PSR was performed on 4 μm formalin-fixed paraffin-
embedded sections that were de-waxed and rehydrated through xylene
and a graded ethanol series. Rehydrated slides were stained for 2 h in PSR
staining solution (equal volumes of 0.1% Direct red 80 (Sigma Aldrich) and
0.1% Fast green (Raymond A Lamb) (both in distilled water) combined in a
1:9 dilution with aqueous Picric acid solution (VWR)), rinsed in tap water,
and dehydrated through a graded ethanol series and xylene before being
coverslipped using DPX mountant (CellPath, UK).
Manual and automated IHC staining were performed as previously
described [69, 85] with the reagents and staining platform used for each
antibody as noted in the accompanying reagent and antibody information
tables (Supplementary Tables 1 and 2).
Analysis of IHC images
The analysis of IHC staining in CCl4 experiments, and for CYP2A5 IHC staining
in Mdm2Ex5/6Δ mice, was performed as previously described [69, 85].
For the analysis of IHC staining for p53 and p21 in Mdm2Ex5/6Δ mice, a
Leica Aperio AT2 slide scanner (Leica Microsystems, UK) was used to scan
stained sections at 20× magnification. Histological scoring was performed
using HALO image analysis software (V3.1.1076.363, Indica Labs).
Quantification of liver damage
A minimum of five random non-overlapping 4× magnification fields were
taken from each H&E stained slide using an Olympus BX51 microscope
with Zen Blue software (Zeiss). From these images, damage was manually
traced and the total damaged area per slide was calculated using imageJ
software.
Cell culture
HepG2 (HB-8065) and SK-Hep-1 (HTB-52) cells were obtained from ATCC
but were not authenticated. Mycoplasma testing was performed when
cells were thawed and semi-regularly thereafter using the MycoAlert
Mycoplasma Detection Kit (Lonza LT07-318). Independent experiments
were performed on cells treated with siRNA and compounds from separate
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passages of each cell line. Stock flasks were maintained in DMEM glucose,
glutamine, and phenol red-free medium (Gibco, A1443001) supplemented
with 4mM glucose (Sigma cat# 49163), 1 mM pyruvate (Gibco cat#
11360088), 1 mM L-Glutamine (Gibco cat# 25030032), penicillin/strepto-
mycin (Gibco cat# 15070063), Gentamycin (Gibco cat# 15750037), and 10%
FBS (Gibco cat# 10091148). Cells were cultured at 37 °C in a humidified
atmosphere of 5% CO2.
Cells were treated with 10 μM Nutlin-3a (Nutlin) (Sigma cat# SML0580)
dissolved in DMSO, 4 mM CCl4 (Sigma cat# 289116) dissolved in DMSO, 10
μM cumene hydroperoxide (Thermo Fisher Scientific cat# C10445)
dissolved in DMSO, or DMSO as vehicle control. For in vitro experiments,
CCl4 was prepared by first combining an 80/20 (v/v) mixture of CCl4 and
DMSO with media to make a 100× stock. The stock was then sonicated for
5 min to disperse the CCl4 mixture and the resulting solution was added
to cells.
Transfection with siRNA
Studies utilising siRNA knockdown were performed as previously described
[69], with siGENOME SMARTpool siRNA constructs (Horizon) used for the
non-targeting siRNA control pool (D-001206-13-05) and to target P53 (M-
003329-03-0005) and CYP2A6 (M-008781-02-0005). Constructs were used
to transfect cell lines at 20 nM concentration using the Lullaby siRNA
transfection reagent and the manufacturer’s recommended reverse
transfection procedure (OZ Biosciences).
Flow cytometry
HepG2 and SK-Hep-1 cells were analysed for cellular ROS levels as
previously described [69]. Data were analysed using FlowJo X 10.0.7r2
(FlowJo, LLC) and median fluorescence intensity values were obtained and
compared across samples.
RNA-seq
Liver samples were isolated and preserved in Allprotect tissue reagent
(Qiagen cat# 76405) (CCl4 samples) or snap frozen on dry ice and stored at
−80 °C until RNA extraction (Mdm2Ex5/6Δ samples). To isolate RNA, tissue
was homogenised using a Precellys tissue homogeniser (Bertin Instru-
ments) and RNA was extracted using the RNeasy Plus Universal mini kit
(Qiagen cat# 73404) (CCl4 samples) or the RNeasy mini kit (Qiagen cat#
74104) (Mdm2Ex5/6Δ samples), all according to the manufacturers’
recommendations. The quality of the purified RNA was tested on an
Agilent 2200 Tapestation using RNA screentape (Agilent). Libraries for
cluster generation and DNA sequencing were prepared as previously
described using an Illumina TruSeq Stranded mRNA LT Kit (CCl4 samples)
or an Illumina TruSeq Stranded mRNA HT Kit (Mdm2Ex5/6Δ samples) [87].
The quality and quantity of the DNA libraries was assessed on an Agilent
2200 Tapestation (D1000 screentape) and Qubit (Thermo Fisher Scientific),
respectively. The libraries were run on the Illumina Next Seq 500 using the
High Output 75 cycles kit (2 × 36 cycles, paired-end reads, single index
for CCl4 samples and 2 × 36 cycles, paired-end reads, dual index for
Mdm2Ex5/6Δ samples).
Analyses of RNA-seq expression data
For CCl4 RNA-seq, Fastq files were generated from the sequencer output
using Illumina’s bcl2fastq (version 2.15.0.4) and quality checks on the raw
data were done using FastQC (version 0.10.1) [88] and FastQ Screen
(version 0.4.2) [89]. Alignment of the RNA-Seq paired-end reads was to the
GRCh38.75 [90] version of the mouse genome and annotation using
Tophat (version 2.0.13) with Bowtie (version 2.2.6.0) [91]. Expression levels
were determined and statistically analysed by a workflow combining
HTSeq (version 2.2.4.0) [92], the R environment (version 3.4.2) [93], and
packages from the Bioconductor data analysis suite [94]. Differential gene
expression analysis was based on the negative binomial distribution using
the DESeq2 package [95]. “Heatmap.2” function of gplots package [96] was
used for hierarchical clustering of significant hits.
For Mdm2Ex5/6Δ RNA-seq, quality checks and trimming on the raw RNA-
Seq data files were done using FastQC (version 0.11.7) [88], FastP [97] and
FastQ Screen (version 0.12.0) [89]. RNA-Seq paired-end reads were aligned
to the GRCh38.92 [90] version of the mouse genome and annotated using
HiSat2 version 2.1.0 [98]. Expression levels were determined and
statistically analysed by a combination of HTSeq version 0.9.1 [92] and the
R environment version 3.4 [93], utilising packages from the Bioconductor
data analysis suite [94] and differential gene expression analysis based on
the negative binomial distribution using the DESeq2 package version
1.18.1 [95].
TCGA analysis
Survival, mutation and expression data were obtained via cBioPortal
[99, 100]. The results here are in whole or part based upon data generated
by the TCGA Research Network (http://cancergenome.nih.gov/), using the
TCGA-LIHC dataset [59].
The optimal cut-off point for high or low expression of CYP2A6 in
survival analyses was determined using the “surv_cutpoint” function of
survminer package in R (0.4.8) [93, 101]. Overall survival data from patients
for each expression group was plotted and analysed using inbuilt tools as
indicated in Prism 7 (Graph Pad). Correlations between CYP2A6 expression
and the ‘P53-induced gene target expression signature’ [14] were assessed
using the “cor” function from base R [93]. Then, the resulting heatmap was
plotted using the function “corrplot” from the corrplot package (Version
0.84) to plot heatmaps [102].
Quantitative RT-PCR
For qPCR analysis of mouse tissue, liver samples were isolated and
preserved in Allprotect tissue reagent (Qiagen cat# 76405). RNA was
extracted as previously described [85]. cDNA was synthesised using the
high capacity RNA-to-cDNA kit (Thermo Fisher Scientific cat# 4387406) and
qPCR reactions were performed on a QuantStudio 5 real-time PCR system
(Thermo Fisher Scientific) using Taqman FAST advanced master mix and
Taqman gene expression assays (all Thermo Scientific) according to the
manufacturer’s recommendations and using the assays listed in Supple-
mental Table 3. Gene expression was quantified relative to the house-
keeping gene Beta-glucuronidase according to the comparative ΔΔCt
method.
For qPCR analysis of human cell lines, RNA was extracted from HepG2
and SK-Hep-1 cells using the RNeasy mini kit (Qiagen cat# 74104)
according to the manufacturer’s recommendations, omitting the optional
additional DNase treatment step. cDNA synthesis and qPCR reactions were
performed as for mouse tissue samples described above. Gene expression
in human cell lines was quantified relative to the housekeeping gene
ACTIN according to the comparative ΔΔCt method.
Data plotting and statistical analysis
Data were plotted using Prism 7 (Graph Pad). The statistical analysis for
each experiment was performed using the test indicated in the
relevant figure legend and multiplicity-adjusted p values using the
built-in analysis tools of Prism 7. Statistical tests were chosen based on
the nature of the comparison being made and the corresponding
standard tests utilised in the field. Underlying assumptions for these
tests, including sample independence, variance equality, and normality
were assumed to be met although not explicitly examined. Figures
were prepared using Illustrator (Adobe). Unless otherwise indicated,
data are represented as mean ± standard error of the mean (SEM) for
error bars. Asterisks denote p value as follows: *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.
DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding
authors upon reasonable request. RNA-seq data discussed in this paper have been
deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series
accession numbers GSE183053 and GSE183082.
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